| Assessment Status | Rapid Review complete |
| HTA ID | 24027 |
| Drug | Crovalimab |
| Brand | Piasky® |
| Indication | For the treatment of adult and paediatric patients 12 years of age or older with a weight of 40 kg and above with paroxysmal nocturnal haemoglobinuria (PNH): (i) In patients with haemolysis with clinical symptom(s) indicative of high disease activity; (ii) In patients who are clinically stable after having been treated with a complement 5 inhibitor for at least the past 6 months |
| Assessment Process | |
| Rapid review commissioned | 11/07/2024 |
| Rapid review completed | 01/08/2024 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that crovalimab not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
